Navigation Links
Solos Endoscopy, Inc. Announces Retirement of 150 Million Common Shares
Date:2/14/2012

BOSTON, Feb. 14, 2012  /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) announced today that the Company's Board of Directors has completed the retirement of one hundred fifty million (150,000,000) common shares held by its officers and directors in exchange for Series B Convertible Preferred Shares. The common shares held by the officers and directors have now been cancelled and returned back to the Company treasury. This transaction represents a reduction of approximately 22% of the Company's issued and outstanding common shares.

The retirement of common shares by the Company's officers and directors will allow for greater flexibility to utilize the assets of Solos for debt reduction, future financing, and services. The Company intends to use proceeds from future financing for the development of new instrument lines as well as further enhancements to its MammoView® instrument line.

"This share retirement allows Solos to maintain the integrity of its market while continuing to develop its new product line.  Management believes in our progress and is willing to take a long term position in the Company's Series B Preferred Shares," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

CONTACT:
AMANDA SEGERSTEN,
RSEGERSTEN@SOLOSENDOSCOPY.COM


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc. is Primed for Growth in 2012
2. Solos Endoscopy, Inc. Reports Significant Sales From Its MammoView® Instrument Line
3. Solos Endoscopy Finishes the 3rd Quarter With a Net Profit
4. Solos Endoscopy Poised for Tremendous Growth in Multi-Billion Dollar Endoscopic Market
5. Solos Endoscopy Goes Google
6. Solos Endoscopy Finishes the 3rd Quarter Strong
7. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
8. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
9. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
10. Solos Endoscopy to Reduce Debt by Over $620,000
11. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)...  International Biophysics Corporation, a global medical device manufacturer based ... 34% revenue growth in 2016 when compared to the previous ... growth was fueled by its AffloVest® sales in ... of its global sales of surgical product lines. ... enter our 25 th year in delivering high-quality, innovative ...
(Date:2/27/2017)... ROCKVILLE, Md. , Feb. 27, 2017 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... its licensee for RGN-137, GtreeBNT Co., Ltd., received ... its Phase 3 clinical trial design for RGN-137 ... dermal wound healing gel that incorporates Thymosin beta ...
Breaking Medicine Technology:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... The threat ... went to work for a company involved in the underground testing of nuclear weapons. ... “Dying for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the ...
(Date:2/27/2017)... ... , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and ... for Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss ... compiled into a single volume a compelling argument that the disease does exist in ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top five ... genders. And the need for advanced services is growing. , Project WE vs ... program, in collaboration with their non-profit partners in their fight against cancer and in ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC ... North America, today announced it would be offering some it’s exclusive product line ... on crafting quality and unique baby clothing/feeding products, will team up with AMAZON ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... (PD) in persons with a specific LRRK2 mutation, according to a study released ... studies have provided evidence of a link between pesticides and incidence of sporadic ...
Breaking Medicine News(10 mins):